Drug Development · us
Sustained tau reduction after subcutaneous injection: Arrowhead RNAi therapy yields early human evidence
ARO-MAPT reduced cerebrospinal fluid total tau by an average of 73% in healthy volunteers 90 days after the last dose. This offers clues about RNAi delivery to the central nervous system, but whether it can improve memory and daily functioning in patients with Alzheimer’s disease remains for patient trials to answer.
Treating brain diseases with RNA interference therapy first requires solving the problem of how the drug reaches its site of action. On October 14, Arrowhead Pharmaceuticals announced interim results from the Phase 1/2a trial of ARO-MAPT: after healthy volunteers received subcutaneous injections, total tau protein in their cerebrospinal fluid declined substantially, with the effect lasting until 90 days after the final dose. The results provide early human evidence for the delivery technology and bring the next question into sharper focus: can lowering tau translate into improvements that patients can perceive?
ARO-MAPT is designed to suppress MAPT gene expression in the central nervous system through RNA interference, reducing tau protein production at its source. Pathological tau aggregation is implicated in Alzheimer’s disease and other neurodegenerative diseases, making it an important target for drug development. However, reducing protein production, clearing existing pathological aggregates, and protecting cognitive function are distinct outcomes that require separate validation.
According to the company’s announcement and S&P Capital IQ’s report on the same event published on MarketScreener, the 2.1 and 6.4 mg/kg groups received doses on days 1, 8, and 15, with average reductions in cerebrospinal fluid total tau of 40% and 69%, respectively, on day 105. The 12.8 mg/kg group received doses on days 1 and 15 and showed an average reduction of 73% on day 105, with a maximum reduction of 85% in an individual participant. These figures come from healthy volunteers and are not efficacy results in patients with Alzheimer’s disease.
Another key finding was that the highest disclosed dose group maintained the reduction three months after the final injection. Based on this, the company suggested the possibility of dosing every three months, or even less frequently. However, the current dosing schedules and follow-up results are insufficient to establish a long-term treatment interval. Changes in cerebrospinal fluid markers also cannot directly describe the drug’s distribution across brain regions or demonstrate that tau tangles in the brain have decreased.
Regarding safety, the company said overall tolerability has been good to date, with most treatment-emergent adverse events being mild. No serious events, deaths, or discontinuations of treatment and study participation due to adverse events were reported. Common events included injection site reactions, puncture site bruising, upper respiratory tract infections, back pain, and headache. However, these remain interim observations from an early trial and cannot establish the safety of repeated dosing over the long term.
This placebo-controlled, dose-escalation trial plans to enroll approximately 64 healthy volunteers and up to 48 patients with early Alzheimer’s disease, including those with mild cognitive impairment and mild dementia due to Alzheimer’s disease. The company said enrollment has been completed across the healthy volunteer groups. It will next complete dosing in the multiple-dose groups and continue recruiting patients, with a data update expected in 2027.
The key step ARO-MAPT has taken so far is therefore the demonstration of a sustained central nervous system-related biomarker response after subcutaneous injection. Progress toward treating Alzheimer’s disease will still require confirmation in patients of its effects on tau pathology, cognition, daily functioning, and disease progression. These results provide a more concrete basis for assessing delivery and duration of action; the answer on clinical benefit remains in subsequent trials.